text:
About 125,000 people are diagnosed with cancer in Australia each year. With population growth and aging this is set to rise to 150,000 new cases each year by 2020.1 in 2 Australian men and 1 in 3 Australian women will be diagnosed with cancer by the age of 85. Cancer is a leading cause of death in Australia. (Source: Cancer Council Australia)
New South Wales
Northern Territory
South Australia
Western Australia
Latest Research Publications
National Organisations (32 links)
The federal government agency established to help reduce the impact of cancer for all Australians. The Website includes extensive information about cancer, healthy living, clinical best practice and other resources.
Cancer Councils are the leading independent funders of cancer research in Australia. They also raise awareness and provide information, support and advocacy.
Cancer Council Helpline - 13 11 20
Cancer Council Australia
Call 13 11 20. a free, confidential telephone information and support service run by Cancer Councils in each state and territory of Australia.
Acoustic Neuroma Association of Australia
A self-help, not-for profit organization founded in 1984. Provides support and information about Acoustic Neuroma.
Australasian Association of Cancer Registries
AACR is a collaborative body representing the 8 Australian state registries, New Zealand Cancer Registry and AIHW. It was formed in 1982 to promote uniformity of collection, classification and collation of cancer data.
Australasian Lung Cancer Trials Group
ALTG is a multi-disciplinary organization dedicated to reducing the incidence, morbidity and mortality of lung and other thoracic cancers and improving the quality of life of these patients, carers and families in Australia and New Zealand through the coordination and facilitation of high quality clinical research.
Australian Association of Smoking Cessation Professionals
AASCP promotes optimal smoking cessation practice in Australia by trained health professionals incorporating evidence-based practice with an ongoing learning o/CPD.
Australian Government
Searchable database of the latest clinical trials in cancer care, including data from the Australian New Zealand Clinical Trials Registry and US ClinicalTrials.gov. Includes a glossary explains what clinical trials are.
Australian Cervical Cancer Foundation
Australian Mesothelioma Registry
AMR monitors all new cases of mesothelioma diagnosed from 1st July 2010 in Australia. In addition, information about asbestos exposure is collected from people with mesothelioma through the Postal Questionnaire and telephone interview.
Australian Oncology Social Work Inc.
A non-profit, incorporated national organisation dedicated to the enhancement of psychosocial services to people with cancer and their families. Created in 2004 by social workers.
Australian Prostate Cancer Research
A national research organisation that partners with leading institutions to develop, fund and deliver national research programs.
Australian Society of Gynaecologic Oncologists
Professional organisation founded in 1986 to promote and improve standards of care of patients with gynaecologic cancer, education/CPD and research.
A member-based organisation, with membership fees and donations used to support and educate members with the most up-to-date, research, treatment and medications.
Cancer Nurses Society of Australia
A professional membership-based organisation founded in 1998.
Clinical Oncological Society of Australia
A national body representing multidisciplinary health professionals whose work encompasses cancer control and care in Australia.
Cooperative Trials Group for Neuro-Oncology
COGNO was established in 2007, to improve outcomes for patients and those affected by brain tumours through clinical trials research.
Fanconi Anaemia Australia Ltd
A public organisation founded in 2006 to provides a variety of support services to families suffering Fanconi Anaemia, in addition to providing broad-based education doctors, carers, families and the general public.
Leukaemia Foundation of Australia
Medical Oncology Group of Australia
The peak representative body for medical oncologists in Australia, founded in 1979.
National Cancer Statistics Clearing House
NCSCH was established in 1986 as the national repository of cancer incidence and mortality statistics in Australia. It is administered by the AIHW and is a collaboration with Australia's cancer registries.
National Health and Medical Research Council
A national body for supporting health and medical research; for developing health advice for the Australian community, health professionals and governments; and for providing advice on health and medical research.
A non-profit organisation aimong to raise awareness of neuroblastoma, raise funds for research and provide support and advice to patients and families.
National Health and Medical Research Council
Established in 1988, the centre supports clinical trials, including international collaboration on trials. Located at the University of Sydney.
A national organisation, incorporated in 2001, which aims to support, educate, advocate, and promote research. The website includes extensive information about ovarian cancer and details of local support groups.
Prostate Cancer Foundation of Australia
A registered charity, founded in 1996, dedicated to reducing the impact of prostate cancer by promoting and funding research, awareness and education programs, and providing evidence-based information and resources, support groups and Prostate Cancer Specialist Nurses.
Skin & Cancer Foundation Australia
A not-for-profit organisation providing a full range of services for the diagnosis and management of skin conditions, including skin cancer.
An independent, volunteer based charity whose focus is to raise funds to provide financial and emotional support, information and counseling for breast cancer patients.
YouthCancer.com.au has been developed by CanTeen as part of the Youth Cancer Networks Program in Australia.
New South Wales (10 links)
B-Mail - Breast Cancer Email list
An unmoderated Email discussion list run by BreastNet / Breast Cancer Institute of New South Wales
Cancer Council New South Wales
An independent, non-government organisation. The site includes details of the national telephone helpline, the Foundation's services and cancer information.
NSW Government
A statewide, government-funded cancer control agency, established in 2003.
Children's Cancer Institute Australia for Medical Research
CCIA is an independent medical research institute dedicated to research into the causes, prevention, and treatments for childhood cancer. Based in the Lowy Cancer Research Centre, UNSW.
Hereditary Cancer Registry - NSW
Cancer Institute NSW
A screening reminder service established in 1990 to provide information and support to people affected by hereditary cancer, their family members, and their doctors in NSW and the ACT.
University of New South Wales
An integrated childhood and adult cancer medical research institute.
Melanoma Institute
Melanoma Institute Australia is a not-for-profit organisation dedicated to preventing and curing melanoma through innovative, world-class research, treatment and education programs. The headquarters / Poche Centre are located in Sydney.
New South Wales Central Cancer Registry
Cancer Institute NSW
A population-based registry that records all new diagnoses of cancer in NSW residents and all deaths from cancer.
A centre dedicated to better understanding and addressing the physical, emotional and practical challenges faced by survivors of adult and childhood cancers.
Westmead Breast Cancer Institute
The site includes information on breast health, screening information, research, personal experiences, and events.
Northern Territory (4 links)
Cancer Council Northern Territory
Cancer Council NT
An independent, non-government organisation. The site includes details of the national telephone helpline, the Foundation's services and cancer information.
Northern Territory Radiation Oncology
Alan Walker Cancer Care Centre, Tiwi
NTRO, part of the Alan Walker Cancer Care Centre, provides Northern Territorians with access to professional, high quality cancer treatment without the need to travel interstate.
Breast Cancer Network Australia
An advocacy group based in Darwin which aims to improve services and conditions for all Territorians affected by breast cancer.
Department of Health, Northern Territory Government
Queensland (10 links)
Australian Prostate Cancer Research Centre – Queensland
One of two disease-specific, consolidated national prostate cancer research centres. APCRC-Q is an initiative between the Queensland University of Technology and the Princess Alexandra Hospital.
Breast and Prostate Cancer Association of Queensland
A volunteer managed charity dedicated to improving breast and prostate cancer services to people living in rural and regional Queensland by providing grants for the education and placement of nurses, research grants, and rural seminars.
An independent, non-government organisation founded in 1961. The site includes details of the national telephone helpline, the Foundation's services and cancer information.
CanSpeak QLD
Founded in 2007 CanSpeak QLD is an independent advocacy and support network, developing partnerships with cancer patients, survivors, family members and health professionals.
Leukaemia Foundation of Queensland
A not-for-profit organisation, founded in 1975, dedicated to the care and cure of patients and families living with blood cancers and related disorders. The site includes details of support services and research.
Queensland Cancer Control Analysis Team
Queensland Government
QCCA was established in 2004 to support clinician led improvements in the safety and quality of cancer services in Queensland.
The Cancer Registry maintains a Register of all cases of cancer diagnosed in Queensland since the beginning of 1982.
Queensland Centre for Gynaecological Cancer
A state-wide service for the management of women with gynaecological cancer working in partnership with Queensland Health. QCGC also has a reseach branch loctaed in the Royal Brisbane and Women's Hospital.
Queensland Institute of Medical Research
The Institute was established in 1945 by the Queensland Government, its work includes an extensive cancer research programme, and includes the Clive Berghofer Cancer Research Centre.
Queensland Youth Cancer Service
Provides support for 15-25 yr old patients with a cancer diagnosis receiving treatment at Princess Alexandra Hospital, Royal Brisbane and Womens Hospital and the Queensland Childrens Cancer Centre at the Royal Childrens Hospital.
South Australia (10 links)
SA Pathology and the University of Adelaide
An independent, non-government organisation founded in 1928. The site includes details of the national telephone helpline, the Foundation's services and cancer information.
A advocacy organisation promoting the perspectives and interests of cancer patients, their carers and supporters to health professionals, government and the public and create a balanced public awareness of cancer.
SA Pathology and the University of Adelaide
CCB studies the fundamental causes of cancer in order to find new ways to prevent and treat the disease.
A childhood cancer support organisation, dedicated to providing emotional, practical and financial support to families in need in South Australia.
Country Cancer Support South Australia
The website aims to assist rural South Australians who have been affected by cancer, by giving practical information on how to cope and who can help.
South Australian Cancer Registry
Government of South Australia
The registry monitors, analyses, reports and makes recommendations on epidemiological, demographic and social indicators for interventions aimed at preventing cancer in South Australia.
South Australian Comprehensive Cancer Consortium
Founded in 2012 to bring together research and clinical expertise across SA, promote translational research, and ensure the best clinical outcomes for cancer patients living in South Australia.
South Australian Prostate Cancer Clinical Outcomes Collaborative
A multidisciplinary group of health professionals comprising urologists, radiation oncologists, nurses and consumers, who undertake clinical prostate cancer and health services research. The site includes extensive prostate cancer information.
Youth Cancer Service South Australia/Northern Territory
Youth Cancer Service (SA/NT)
Provides support for for young people aged 15 to 25 years who have recently been diagnosed with cancer.
Tasmania (3 links)
a not-for-profit organisation that works to minimise the incidence and impact of cancer on all Tasmanians through advocacy, raising awareness of cancer prevention and offering advice and support for those living with cancer and their carers.
Victoria (13 links)
Australian Genomics and Clinical Outcomes of Glioma
AGOG Epi is a study that aims to investigate the genetic, lifestyle and environmental factors that may cause glioma brain tumours. Run by run by Cancer Council Victoria and other partners.
An independent, non-government organisation founded in 1936. The site includes details of the national telephone helpline, the Foundation's services and cancer information.
Department of Health, Victoria
Ludwig Institute for Cancer Research, Melbourne-Austin Branch
LICR Melbourne-Austin Branch
Includes details of research, clinical trials, resources, and information for students.
A public hospital, founded in 1950, dedicated to cancer treatment, research and education. There are 5 Peter Mac clinics accros Melbourne and Victoria.
Founded in 1980, SunSmart promotes a balance between the benefits and harms of ultraviolet (UV) radiation exposure and the links with vitamin D. The site includes educational information for schools, home, and workplace.
Victorian Breast Cancer Research Consortium
Established in 1997 this is a consortium formed between eight Melbourne medical research institutes and The Cancer Council Victoria. The site includes details of current and past research.
The Agency has been established to facilitate cancer research across Victoria. It aims to streamline research, and its translation into the clinical setting to improve clinical practice and care of cancer patients.
A not-for-profit consortium of tissue banks, established in 2006, to support research. Supported by the Victorian Government through the Victorian Cancer Agency.
A state population-based cancer registry established 1939.
Victorian Comprehensive Cancer Centre - Project
State Government of Victoria
Work in progress to develop a purpose-built facility for cancer research, treatment and care in the Melbourne suburb of Parkville, Victoria.
Walter and Eliza Hall Institute of Medical Research
Includes divisions of Cancer and Haematology, Development and Cancer, Molecular Genetics of Cancer, and Stem Cells and Cancer.
Western Australia (8 links)
Cancer Council Western Australia
a non-profit / non-government cancer organisation founded in 1947. The site includes details of services, medically reviewed cancer information, and research.
Founded in 1984 Cancer Support WA's programs include: cancer wellness courses and seminars; support groups; counselling; complementary therapies; and nutrition, meditation and yoga.
Children's Leukaemia & Cancer Research Foundation (Inc)
The Foundation was formed in 1983 by parents of children with cancer, concerned supporters and with the support of the children's hospital to establish a childhood leukaemia and cancer research facility in Western Australia.
Formed in 1997 to advise the Cancer Council WA on all clinical aspects of cancer. WACOG also aims to promote and facilitate cooperative studies on cancer.
Western Australian Cancer Registry
Government of Western Australia
The site includes statistics from the registry and details of research.
Western Australian Institute for Medical Research
Latest Research Publications
Safe handling and administration of MABS: the guidance.
Br J Nurs. 2015; 24(16 Suppl 1):S14-20 [PubMed] Related Publications
Benefit Cost Analysis of Three Skin Cancer Public Education Mass-Media Campaigns Implemented in New South Wales, Australia.
PLoS One. 2016; 11(1):e0147665 [PubMed] Free Access to Full Article Related Publications
Timeliness of lung cancer care in Victoria: a retrospective cohort study.
Med J Aust. 2016; 204(2):75.e1-9 [PubMed] Related Publications
DESIGN, SETTING AND PARTICIPANTS: A retrospective cohort study, conducted in six public and two private Victorian hospitals, of 1417 patients aged 18 years or more who were diagnosed between July 2011 and October 2014 with an incident case of lung cancer identified by International Classification of Diseases, 10th revision codes (C34.0-C34.9, Z85.1, Z85.2) on the basis of either a clinical or pathological diagnosis.
OUTCOME MEASURES: Time intervals between referral, diagnosis and initial definitive management.
RESULTS: The median time from referral to diagnosis was 15 days (interquartile range [IQR], 5-36); from diagnosis to initial definitive management, 30 days (IQR, 6-84); and from referral to initial definitive management, 53 days (IQR, 25-106). Factors that were significantly associated with delay between referral and initial definitive management include declining or not being referred to palliative care (hazard ratio [HR], v patients referred for palliation, 0.73; 95% CI, 0.62-0.86; P < 0.001), and being treated in a public hospital (HR, v patients managed in a private hospital, 0.55; 95% CI, 0.48-0.64; P < 0.001). The median time from referral to initial definitive management in public and private hospitals was 61 days (IQR, 35-118) and 30 days (IQR, 13-76) respectively; 48% of patients in public hospitals waited longer than the British National Health Service target of a maximum 62 days between referral and first definitive treatment.
CONCLUSION: There are significant delays at various stages of the patient journey after referral for initial definitive management. Having a greater understanding of these delays will enable strategies to be developed that improve the timeliness of care for patients with lung cancer.
Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
Occup Environ Med. 2016; 73(3):187-94 [PubMed] Related Publications
METHODS: Data on 10 930 people with malignant pleural mesothelioma (MPM) and 640 people with malignant peritoneal mesothelioma diagnosed in Australia during 1982-2009 were analysed. Observed incidence rate trends were quantified. Incidence rates were projected up to 2030 using observed incident cases during 1982-2012. The relative per-decade change in excess mortality during 1999-2009 was estimated.
RESULTS: During 1982-2009, acceleration in MPM age-standardised incidence rates were highest for women and those aged 75 years and above, with average annual percentage changes of +4.9 (95% CI 3.6 to 6.2) and +7.2 (95% CI 5.4 to 9.0), respectively. Age-standardised incidence rates for men with MPM aged 0-64 years decelerated rapidly during 2003-2009, an average annual percentage change of -5.1% (95% CI -7.6% to -2.5%). Overall, male age-specific MPM incidence rates in the age group of 65-74 year during 2010-2030 are projected to decline with rates projected to increase for older men and women with MPM. There was a statistically significant 16% relative reduction in the excess mortality rate (EMR) up to 5 years postdiagnosis for people diagnosed with malignant pleural and peritoneal mesothelioma combined in 2009 compared with those diagnosed in 1999, an EMR ratio of 0.84 (95% CI 0.77 to 0.92).
CONCLUSIONS: Australia's malignant mesothelioma incidence rates appear to have reached maximum levels but with differences over time by age, gender and tumour location. Improvements over time in survival provide a glimpse of hope for this almost invariably fatal disease.
Apple intake is inversely associated with all-cause and disease-specific mortality in elderly women.
Br J Nutr. 2016; 115(5):860-7 [PubMed] Related Publications
The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).
Eur J Cancer. 2016; 55:15-26 [PubMed] Related Publications
PATIENTS AND METHODS: Eligible patients with T3N0-2M0 rectal cancer completed the European Organisation for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30) and the colorectal cancer specific module (QLQ C38) at randomisation and 1, 2, 3, 6, 9 and 12 months later.
RESULTS: Of 326 patients randomised, 297 (SC 143, LC 154) were eligible for completion of HRQOL questionnaires. Baseline scores were comparable across the SC and LC groups. Patients reported low scores on sexual functioning and sexual enjoyment. Defaecation problems were the worst of the symptoms at baseline. Surgery had the most profoundly negative effect on HRQOL, seen in both the SC and LC treatment groups to the same extent. The most severely affected domains were physical function and role function and the most severely affected symptoms were fatigue, pain, appetite, weight loss and male sexual problems. Most domains and symptoms returned to baseline levels by 12 months apart from body image, sexual enjoyment and male sexual problems. Future perspective was better than prior to treatment.
CONCLUSION: There is no overall difference in HRQOL between SC and LC neoadjuvant treatment strategies, in the first 12 months, after surgery. In the immediate postoperative period HRQOL was adversely affected in both groups but for the most part was temporary. Some residual sexual functioning concerns persisted at 12 months.
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
Medicine (Baltimore). 2016; 95(2):e2491 [PubMed] Free Access to Full Article Related Publications
Lymphology. 2015; 48(2):80-92 [PubMed] Related Publications
Lateral pelvic compartment excision during pelvic exenteration.
Br J Surg. 2015; 102(13):1710-7 [PubMed] Related Publications
METHODS: Patients undergoing pelvic exenteration between 1994 and 2014 were eligible for review.
RESULTS: Two hundred consecutive patients who had en bloc resection of the lateral compartment were included. R0 resection was achieved in 66·5 per cent of 197 patients undergoing surgery for cancer and 68·9 per cent of planned curative resections. For patients with colorectal cancer, a clear resection margin was associated with a significant overall survival benefit (P = 0·030). Median overall and disease-free survival in this group was 41 and 27 months respectively. Overall 1-, 3- and 5-year survival rates were 86, 46 and 35 per cent respectively. No predictors of survival were identified on univariable analysis other than margin status and operative intent. Excision of the common or external iliac vessels or sciatic nerve did not confer a survival disadvantage.
CONCLUSION: The continuing evolution of radical pelvic exenteration techniques has seen an improvement in R0 margin status from 21 to 66·5 per cent over a 20-year interval by routine adoption of a more lateral anatomical plane. Five-year overall survival rates are comparable with those for more centrally based tumours.
Olfactory Neuroblastoma: Fate of the Neck--A Long-term Multicenter Retrospective Study.
Otolaryngol Head Neck Surg. 2016; 154(2):383-9 [PubMed] Related Publications
STUDY DESIGN: Multicenter case series with retrospective chart review.
SETTING AND SUBJECTS: In sum, 113 patients with a histopathologic diagnosis of olfactory neuroblastoma across 6 tertiary hospitals in Australia and the United States.
METHODS: Treatment modalities for the primary site and neck included surgery, radiotherapy, and combined therapy. Treatment outcomes were measured in relation to date of primary treatment, and long-term follow-up was recorded. Disease-free survival was calculated as time for patients to develop delayed neck disease following primary treatment.
RESULTS: A total of 113 patients (46 females, 49.7 ± 13.2 years) were identified with a median follow-up of 41.5 months (interquartile range, 58.2); 7.1% of patients presented with primary neck disease, while 8.8% of patients presented with delayed neck disease. Neck disease was present in patients with Hyams grade II (22.2%), III (55.6%), and IV (22.2%) lesions (χ(2) = 5.66, P = .13). Histologic grade was higher in patients with primary neck disease (χ(2) = 16.22, P = .001). Positive surgical margins were associated with a higher risk of delayed neck disease as compared with clear surgical margin (17.9% vs 5%, P = .034).
CONCLUSION: Neck metastasis is an important clinical consideration for olfactory neuroblastoma at presentation and in surveillance. Primary treatment of the neck could be considered in select patients. Long-term surveillance of the neck and primary site is essential.
Spontaneous regression of CIN2 in women aged 18-24 years: a retrospective study of a state-wide population in Western Australia.
Acta Obstet Gynecol Scand. 2016; 95(3):291-8 [PubMed] Related Publications
MATERIAL AND METHODS: A retrospective cohort study of Western Australian women aged 18-24 years diagnosed with CIN2 on cervical biopsy from 1 January 2001 to 31 December 2010. Women who had not received treatment at ≥4 months following CIN2 diagnosis were classified as managed 'conservatively'. Subsequent cervical cytology and/or biopsy test results were used to report lesion regression (absence of dysplasia or an epithelial lesion of lower grade than CIN2) and disease persistence (CIN2, CIN3 or ACIS).
RESULTS: Follow-up data were available for 2417 women of whom 924 (38.2%) were 'conservatively' managed. In all, 152 (16.4%) conservatively managed women had a lesion more severe than CIN2 detected within 24 months of initial diagnosis, of which 144 were CIN3 and eight were ACIS. There was no statistically significant association between rates of regression and patient age, Socio-economic Indexes for Areas or Accessibility/Remoteness Index of Australia indices. The 2-year regression rate for CIN2 was estimated to be 59.5% (95%CI 0.5-0.6) in this cohort of women.
CONCLUSION: In conservatively managed young women with CIN2 there was a high rate of spontaneous disease regression. Thus, excisional or ablative treatments may be avoided in selected patients who receive appropriate counseling and who are able to comply with more intensive and prolonged follow-up requirements.
The Value of Audio Devices in the Endoscopy Room (VADER) study: a randomised controlled trial.
Med J Aust. 2015; 203(11):472-5 [PubMed] Related Publications
DESIGN AND SETTING: A single-centre, prospective, randomised controlled trial conducted in an endoscopy suite within a quaternary-centre gastroenterology unit, Melbourne, Australia.
MAIN OUTCOME MEASURES: The primary outcome measures were procedure time, polyp detection rate (PDR) and adenoma detection rate (ADR). The secondary outcome measure was adenomas per colonoscopy (APC).
RESULTS: 103 colonoscopies were analysed: 58 in the SWM group and 45 in the PM group. Bowel preparation was assessed as good or excellent in 57% of the SWM group compared with 69% of the PM group (P < 0.01). The PDR was significantly higher in the SWM group than in the PM group (60% v 35%; P = 0.006). Similarly, the ADR was significantly higher in the SWM group than in the PM group (48% v 27%; P = 0.01). The APC in the SWM group was 84% compared with 35% in the PM group (P = 0.01).
CONCLUSION: SWM compared with PM improves key quality outcomes in colonoscopy, despite poorer bowel preparation.
HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Anticancer Res. 2015; 35(12):6667-70 [PubMed] Related Publications
MATERIALS AND METHODS: We studied the HER2 codon 655 (rs1136201) polymorphism in 80 Austrian patients with BC and 100 healthy volunteers by pyrosequencing and polymerase chain reaction. Associations between codon 655 allelic variants and clinicopathological variables (e.g. age, stage of disease, tumor type, grading, and receptor status) were studied with 2×2 tables.
RESULTS: The genotypic distributions in patients with BC (AA: 63.75%, AG: 32.5%, GG: 3.75%) and controls (AA: 63%, AG: 34%, GG: 3.7%) were virtually identical (odds ratio=1.03, 95% confidence interval=0.56-1.90). A non-significant link between carrying at least one G allele and more aggressive tumor type (estrogen receptor-negative p=0.08, G3 tumor p=0.19) was observed.
CONCLUSION: Genotypic variation within the codon 655 of HER2 does not alter the BC risk in Caucasian Austrian women. The association between the G allele and more aggressive tumor types requires further investigation.
Differences in the Pathological Diagnosis and Repeat Craniotomy Rates in Cerebral Tumors Undergoing Biopsy or Resection in an Urban Versus Regional Center.
Medicine (Baltimore). 2015; 94(47):e2131 [PubMed] Related Publications
Geographic variation in the intended choice of adjuvant treatments for women diagnosed with screen-detected breast cancer in Queensland.
BMC Public Health. 2015; 15:1204 [PubMed] Free Access to Full Article Related Publications
METHODS: Linked population-based datasets from BreastScreen Queensland and the Queensland Cancer Registry during 1997-2008 for women aged 40-89 years were used. We adopted a Bayesian shared spatial component model to evaluate the relative intended use of each adjuvant therapy across 478 areas as well as common spatial patterns between treatments.
RESULTS: Women living closer to a cancer treatment facility were more likely to intend to use adjuvant therapy. This was particularly marked for radiotherapy when travel time to the closest radiation facility was 4 + h (OR =0.41, 95 % CrI: [0.23, 0.74]) compared to <1 h. The shared spatial effect increased towards the centres with concentrations of radiotherapy facilities, in north-east (Townsville) and south-east (Brisbane) regions of Queensland. Moreover, the presence of residual shared spatial effects indicates that there are other unmeasured geographical barriers influencing women's treatment choices.
CONCLUSIONS: This highlights the need to identify the additional barriers that impact on treatment intentions among women diagnosed with screen-detected breast cancer, particularly for those women living further away from cancer treatment centers.
Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts.
J Hypertens. 2016; 34(1):149-55 [PubMed] Related Publications
METHOD: Eighty-six thousand five hundred and ninety-three participants from the Australian and New Zealand Diabetes and Cancer Collaboration were linked to the National Death Index and Australian Cancer Database. Cox proportional hazards models estimated hazard ratios and 95% confidence intervals (95% CI) for the association of treated and untreated hypertension with cancer incidence and mortality.
RESULTS: Over a median follow-up of 15.1 years, 12 070 incident and 4350 fatal cancers were identified. Untreated and treated hypertension, compared with normotension, were associated with an increased risk for cancer incidence [hazard ratio 1.06, 95% CI (1.00-1.11) and 1.09 (1.02-1.16) respectively], and cancer mortality (1.07, 0.98-1.18) and (1.15, 1.03-1.28), respectively. When compared with untreated hypertension, treated hypertension did not have a significantly greater risk for cancer incidence (1.03, 0.97-1.10) or mortality (1.07, 0.97-1.19). A significant dose-response relationship was observed between graded hypertension and cancer incidence and mortality; Ptrend = 0.053 and Ptrend = 0.001, respectively. When stratified by treatment status, these relationships remained significant in untreated, but not in treated, hypertension.
CONCLUSION: Hypertension, both treated and untreated, is associated with a modest increased risk for cancer incidence and mortality. Similar risks in treated and untreated hypertension suggest that the increased cancer risk is not explained by the use of antihypertensive treatment.
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
Eur J Cancer. 2015; 51(18):2792-9 [PubMed] Article available free on PMC after 01/12/2016 Related Publications
METHODS: We compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.
RESULTS: Among 132 samples, putative resistance mechanisms were identified in 58%, including NRAS or KRAS mutations (20%), BRAF splice variants (16%), BRAF(V600E/K) amplifications (13%), MEK1/2 mutations (7%), and non-mitogen-activated protein kinase pathway alterations (11%). Marked heterogeneity was observed within tumors and patients; 18 of 19 patients (95%) with more than one progression biopsy had distinct/unknown drivers of resistance between samples. NRAS mutations were associated with vemurafenib use (p = 0.045) and intracranial metastases (p = 0.036), and MEK1/2 mutations correlated with hepatic progression (p = 0.011). Progression-free survival and overall survival were similar across resistance mechanisms. The median survival after disease progression was 6.9 months, and responses to subsequent BRAF and MEK inhibition were uncommon (2 of 15; 13%). Post-progression outcomes did not correlate with specific acquired BRAFi-resistance mechanisms.
CONCLUSIONS: This is the first study to systematically characterise the clinical implications of particular acquired BRAFi-resistance mechanisms in patients with BRAF-mutant melanoma largest study to compile the landscape of resistance. Despite marked heterogeneity of resistance mechanisms within patients, NRAS mutations correlated with vemurafenib use and intracranial disease involvement.
In the digital era, architectural distortion remains a challenging radiological task.
Clin Radiol. 2016; 71(1):e35-40 [PubMed] Related Publications
MATERIALS AND METHODS: Forty-one experienced breast screen readers (20 US and 21 Australian) were asked to read a single test set of 30 digitally acquired mammographic cases. Twenty cases had abnormal findings (10 with AD, 10 non-AD) and 10 cases were normal. Each reader was asked to locate and rate any abnormalities. Lesion and case-based performance was assessed. For each collection of readers (US; Australian; combined), jackknife free-response receiver operating characteristic (JAFROC), figure of merit (FOM), and inferred receiver operating characteristic (ROC), area under curve (Az) were calculated using JAFROC v.4.1 software. Readers' sensitivity, location sensitivity, JAFROC, FOM, ROC, Az scores were compared between cases groups using Wilcoxon's signed ranked test statistics.
RESULTS: For lesion-based analysis, significantly lower location sensitivity (p=0.001) was shown on AD cases compared with non-AD cases for all reader collections. The case-based analysis demonstrated significantly lower ROC Az values (p=0.02) for the first collection of readers, and lower sensitivity for the second collection of readers (p=0.04) and all-readers collection (p=0.008), for AD compared with non-AD cases.
CONCLUSIONS: The current work demonstrates that AD remains a challenging task for readers, even in the digital era.
The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients.
Eur J Cancer. 2015; 51(18):2808-19 [PubMed] Related Publications
METHODS: Data from 25 EORTC randomized controlled trials was pooled. EORTC QLQ-C30 mean scores for the cancer cohort and five general population cohorts were compared to assess the impact of cancer on patients' HRQOL. Within the cancer cohort, multiple linear regressions (two-sided level P-value = 0.05 adjusted for multiple testing.) were used to investigate the association between age and HRQOL, adjusted for gender, WHO performance status (PS), distant metastasis and stratified by cancer site. A difference of 10 points on the 0-100 scale was considered clinically important.
RESULTS: Cancer patients generally have worse HRQOL compared to the general population, but the specific HRQOL domains impaired vary with age. When comparing the cancer versus the general population, young cancer patients had worse financial problems, social and role functioning, while the older cancer groups had more appetite loss. Within the cancer cohort, HRQOL was worse with increasing age for physical functioning and constipation, and better with increasing age for social functioning, insomnia and financial problems (all p < 0.05).
CONCLUSION: HRQOL is impaired in cancer patients compared to the general population, but the impact on specific HRQOL domains varies by age. Within the cancer population, some HRQOL components improve with age while others deteriorate. Optimal care for older cancer patients should target HRQOL domains most relevant to this population.
Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy.
J Am Acad Dermatol. 2016; 74(1):102-7 [PubMed] Related Publications
METHODS: This was a retrospective review of 807 consecutive WLEs of melanomas diagnosed after complete excisional biopsy. All specimens were reviewed by a single dermatopathologist. Risk of residual or locally metastatic disease was analyzed using univariate and multivariate logistic regression models.
RESULTS: In the 807 WLE specimens, further melanoma was found in 34 cases (4.2%; 95% confidence interval [CI] 2.9-5.8). Residual primary melanoma was found in 33 of these. On univariate analysis, features associated with residual or locally metastatic disease were histologic subtype (odds ratio 3.0; 95% CI 1.3-7.1, P = .01) and tumor location (odds ratio 7.3; 95% CI 2.0-26.6, P < .01). On multivariate analysis, lentigo maligna was independently associated with melanoma remaining in WLE specimens (odds ratio 2.7; 95% CI 1.0-7.3, P = .04).
CONCLUSION: Residual melanoma in WLE specimens after histologically assessed complete excisional biopsy is not uncommon. Patients with lentigo maligna subtype melanomas are most at risk. Our findings indicate that the procedure of WLE is most important therapeutically for its role in controlling the primary tumor, rather than in preventing local metastatic recurrence.
Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study.
Int J Cancer. 2016; 138(8):1905-14 [PubMed] Related Publications
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Lancet Oncol. 2015; 16(16):1617-29 [PubMed] Related Publications
METHODS: We did an open-label, randomised, multicentre, phase 3 study at 59 centres in Australia, Czech Republic, and Italy. We enrolled transplant-eligible patients with newly diagnosed myeloma aged 65 years or younger. Patients received a common induction with four 28-day cycles of lenalidomide (25 mg, days 1-21) and dexamethasone (40 mg, days 1, 8, 15, and 22) and subsequent chemotherapy with cyclophosphamide (3 g/m(2)) followed by granulocyte colony-stimulating factor for stem-cell mobilisation and collection. Using a 2 × 2 partial factorial design, we randomised patients to consolidation with either chemotherapy plus lenalidomide (six cycles of cyclophosphamide [300 mg/m(2), days 1, 8, and 15], dexamethasone [40 mg, days 1, 8, 15, and 22], and lenalidomide [25 mg, days 1-21]) or two courses of high-dose melphalan (200 mg/m(2)) and ASCT. We also randomised patients to maintenance with lenalidomide (10 mg, days 1-21) plus prednisone (50 mg, every other day) or lenalidomide alone. A simple randomisation sequence was used to assign patients at enrolment into one of the four groups (1:1:1:1 ratio), but the treatment allocation was disclosed only when the patient reached the end of the induction and confirmed their eligibility for consolidation. Both the patient and the treating clinician did not know the consolidation and maintenance arm until that time. The primary endpoint was progression-free survival assessed by intention-to-treat. The trial is ongoing and some patients are still receiving maintenance. This study is registered at ClinicalTrials.gov, number NCT01091831.
FINDINGS: 389 patients were enrolled between July 6, 2009, and May 6, 2011, with 256 eligible for consolidation (127 high-dose melphalan and ASCT and 129 chemotherapy plus lenalidomide) and 223 eligible for maintenance (117 lenalidomide plus prednisone and 106 lenalidomide alone). Median follow-up was 52·0 months (IQR 30·4-57·6). Progression-free survival during consolidation was significantly shorter with chemotherapy plus lenalidomide compared with high-dose melphalan and ASCT (median 28·6 months [95% CI 20·6-36·7] vs 43·3 months [33·2-52·2]; hazard ratio [HR] for the first 24 months 2·51, 95% CI 1·60-3·94; p<0·0001). Progression-free survival did not differ between maintenance treatments (median 37·5 months [95% CI 27·8-not evaluable] with lenalidomide plus prednisone vs 28·5 months [22·5-46·5] with lenalidomide alone; HR 0·84, 95% CI 0·59-1·20; p=0·34). Fewer grade 3 or 4 adverse events were recorded with chemotherapy plus lenalidomide than with high-dose melphalan and ASCT; the most frequent were haematological (34 [26%] of 129 patients vs 107 [84%] of 127 patients), gastrointestinal (six [5%] vs 25 [20%]), and infection (seven [5%] vs 24 [19%]). Haematological serious adverse events were reported in two (2%) patients assigned chemotherapy plus lenalidomide and no patients allocated high-dose melphalan and ASCT. Non-haematological serious adverse events were reported in 13 (10%) patients assigned chemotherapy plus lenalidomide and nine (7%) allocated high-dose melphalan and ASCT. During maintenance, adverse events did not differ between groups. The most frequent grade 3 or 4 adverse events were neutropenia (nine [8%] of 117 patients assigned lenalidomide plus prednisone vs 14 [13%] of 106 allocated lenalidomide alone), infection (eight [8%] vs five [5%]), and systemic toxicities (seven [6%] vs two [2%]). Non-haematological serious adverse events were reported in 13 (11%) patients assigned lenalidomide plus prednisone versus ten (9%) allocated lenalidomide alone. Four patients died because of adverse events, three from infections (two during induction and one during consolidation) and one because of cardiac toxic effects.
INTERPRETATION: Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide.
FUNDING: Celgene.
Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
J Natl Cancer Inst. 2016; 108(2) [PubMed] Article available free on PMC after 01/02/2017 Related Publications
METHODS: Pedigree data from CRC patients in 11 North American, European, and Australian cohorts (6 clinic- and 5 population-based sites) were used to calculate predicted probabilities of pathogenic MLH1, MSH2, or MSH6 gene mutations by each model and gene-specific predictions by MMRPro and PREMM1,2,6. We examined discrimination with area under the receiver operating characteristic curve (AUC), calibration with observed to expected (O/E) ratio, and clinical usefulness using decision curve analysis to select patients for further evaluation. All statistical tests were two-sided.
RESULTS: Mutations were detected in 539 of 2304 (23%) individuals from the clinic-based cohorts (237 MLH1, 251 MSH2, 51 MSH6) and 150 of 3451 (4.4%) individuals from the population-based cohorts (47 MLH1, 71 MSH2, 32 MSH6). Discrimination was similar for clinic- and population-based cohorts: AUCs of 0.76 vs 0.77 for MMRPredict, 0.82 vs 0.85 for MMRPro, and 0.85 vs 0.88 for PREMM1,2,6. For clinic- and population-based cohorts, O/E deviated from 1 for MMRPredict (0.38 and 0.31, respectively) and MMRPro (0.62 and 0.36) but were more satisfactory for PREMM1,2,6 (1.0 and 0.70). MMRPro or PREMM1,2,6 predictions were clinically useful at thresholds of 5% or greater and in particular at greater than 15%.
CONCLUSIONS: MMRPro and PREMM1,2,6 can well be used to select CRC patients from genetics clinics or population-based settings for tumor and/or germline testing at a 5% or higher risk. If no MMR deficiency is detected and risk exceeds 15%, we suggest considering additional genetic etiologies for the cause of cancer in the family.
Do teleoncology models of care enable safe delivery of chemotherapy in rural towns?
Med J Aust. 2015; 203(10):406-6.e6 [PubMed] Related Publications
DESIGN: A quasi-experimental design comparing two patient groups.
SETTING: TCC and Mount Isa Hospital, which both operate under the auspices of the Townsville Teleoncology Network (TTN).
PARTICIPANTS: Eligible patients who received chemotherapy at TCC or Mt Isa Hospital between 1 May 2007 and 30 April 2012.
INTERVENTION: Teleoncology model for managing cancer patients in rural towns.
MAIN OUTCOME MEASURES: Dose intensity (doses, number of cycles and lines of treatment) and toxicity rates (rate of serious side effects, hospital admissions and mortality).
RESULTS: Over 5 years, 89 patients received a total of 626 cycles of various chemotherapy regimens in Mount Isa. During the same period, 117 patients who received a total of 799 cycles of chemotherapy at TCC were eligible for inclusion in the comparison group. There were no significant differences between the Mount Isa and TCC patients in most demographic characteristics, mean numbers of treatment cycles, dose intensities, proportions of side effects, and hospital admissions. There were no toxicity-related deaths in either group.
CONCLUSION: It appears safe to administer chemotherapy in rural towns under the supervision of medical oncologists from larger centres via teleoncology, provided that rural health care resources and governance arrangements are adequate.
Life expectancy discussions in a multisite sample of Australian medical oncology outpatients.
Med J Aust. 2015; 203(10):405-5.e7 [PubMed] Related Publications
DESIGN: Cross-sectional survey.
SETTING: Eleven large Australian medical oncology treatment centres.
PARTICIPANTS: A total of 1431 medical oncology outpatients participated (81% consent rate). Eligible patients were approached between September 2012 and May 2014.
MAIN OUTCOME MEASURES: Patients indicated whether the information about life expectancy they received aligned with their preferences.
RESULTS: Almost one in four patients (24%) received too little information, 4% received too much, and 50% received all the information they wanted; 22% of patients neither wanted nor received information about life expectancy. Patients were more likely to receive too little information if they were not in remission (odds ratio [OR], 1.77), did not know their cancer stage at diagnosis (OR, 3.64), or were anxious (OR, 1.48) or depressed (OR, 1.48). Patients had greater odds of receiving too much information if they were younger (OR, 1.45), had more advanced cancer (OR, 2.01) or did not know their cancer stage at diagnosis (OR, 4.42).
CONCLUSIONS: That fact that 28% of cancer patients did not receive their desired level of information about life expectancy highlights the difficulties associated with discussing this sensitive topic. To ensure that life expectancy discussions correspond with patient preferences, clinicians should routinely ask patients whether they want to know this information, in what format, and at which level of detail.
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Transplantation. 2016; 100(1):116-25 [PubMed] Article available free on PMC after 01/02/2017 Related Publications
METHODS: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint.
RESULTS: Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most from sirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874).
CONCLUSIONS: Sirolimus in LTx recipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.
Cumulative Doses of T-Cell Depleting Antibody and Cancer Risk after Kidney Transplantation.
PLoS One. 2015; 10(11):e0139479 [PubMed] Article available free on PMC after 01/02/2017 Related Publications
Papillary Immature Metaplasia of the Anal Canal: A Low-grade Lesion That Can Mimic a High-grade Lesion.
Am J Surg Pathol. 2016; 40(3):348-53 [PubMed] Related Publications
Addressing unresolved tensions to build effective partnerships: lessons from an Aboriginal cancer support network.
Int J Equity Health. 2015; 14:122 [PubMed] Article available free on PMC after 01/02/2017 Related Publications
METHODS: Data were collected through semi-structured interviews with 24 participants purposively selected among Indigenous and mainstream healthcare service providers, and group members and clients. Interviews were audiotaped and transcribed verbatim. Transcripts were subjected to inductive thematic analysis. NVivo was used to manage the data and assist in the data analysis. Rigour was enhanced through team member checking, coding validation and peer debriefing.
RESULTS: Flexibility and a resistance to formal structuring were at the core of how the group operated. It was acknowledged that the network partly owned its success to its fluid approach; however, most mainstream healthcare service providers believed that a more structured approach was needed for the group to be sustainable. This was seen as acting in opposition to the flexible, organic approach considered necessary to adequately respond to Indigenous women's needs. At the core of these tensions were opposing perspectives on the constructs of 'structure' and 'flexibility' between Indigenous and non-Indigenous participants.
CONCLUSIONS: Despite the group's achievements, unresolved tensions between opposing perspectives on how a support group should operate negatively impacted on the working relationship between the group and mainstream service providers, and posed a threat to the Network's sustainability. Our results support the need to acknowledge and address different perspectives and world views in order to build strong, effective partnerships between service providers and Indigenous communities.
Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study.
Carcinogenesis. 2016; 37(1):30-8 [PubMed] Article available free on PMC after 01/01/2017 Related Publications


text:
Penny from Heaven
- Brief Synopsis:
- It's 1953 and 11-year-old Penny dreams of a summer of butter pecan ice cream, swimming, and baseball. But nothing' s that easy in Penny's family. For starters, she can't go swimming because her mother's afraid she'll catch polio at the pool. To make matters worse, her favorite uncle is living in a car. Her Nonny cries every time her father's name is mentioned. And the two sides of her family aren't speaking to each other!
- Long Synopsis:
- Book Quality:
- Publisher Quality
- 9780375849268
- Publisher:
- Random House
- Date of Addition:
- 11/15/10
- Copyright Date:
- 2006
- Copyrighted By:
- Jennifer L. Holm
- Adult content:
- No
- Language:
- English
- Categories:
- History, Children's Books, Literature and Fiction, Teens
- Grade Levels:
- Seventh grade, Sixth grade, Fifth grade, Fourth grade
- Submitted By:
- Bookshare Staff
- Usage Restrictions:
- This is a copyrighted book.
Reviews of Penny from Heaven (0 reviews)
0 - No Rating Yet

subset: commoncrawl


text:
Customer Gallery - See our customer gallery
Availability: In Stock
Looks like your having the family for dinner in our Adult Deadly Chef Costume. Wonder who you will be having for dessert?
Costume Includes:
The Adult Deadly Chef Costume includes a pair of blue and white checked trousers and a white blood stained chef's jacket.
Also included with the Halloween outfit is a matching blood covered hat and an apron with 'THE FAMILY BUTCHER' printed on the front and attached eyes and ears.
Sizes for this costume are:
It was just as seen in the picture, can't wait to wear it on Halloween night, cooking dinner for 12 people.
Have a question about this product? Why not get in touch by completing the boxes below.
Got this costume? Want your photo to appear here? Tag your Instagrams with @jokersmasquerade and #jokers64186.How do I tag my photos?


text:
Job Overview
The National Endowment for the Arts, an independent Federal agency and the official arts organization for the United States government, supports the advancement of artistic excellence, creativity, and innovation. We are motivated by the vision of a Nation in which the arts enrich the lives of all Americans and enhance the livability of communities. If you share our vision, please consider joining us.
This position is located in the Visual Arts Division, Office of the Deputy Chairman for Programs and Partnerships, at the National Endowment for the Arts.
This position is advertised concurrently with NEA-TR-14-1051263 (DEU), using Competitive Examining procedures.
Applications will be accepted from current and former Federal employees with competitive status or who are eligible for consideration under a special appointing authority (e.g., VRA, Schedule A, Peace Corps, etc.).
Applications will also be accepted from a veteran who is a preference eligible or who has separated from the Armed Forces under Honorable conditions after approximately 3 years or more of continuous active service. Additional information on veterans preference is available at: http://www.fedshirevets.gov/job/veterans.aspx.
If you are a current career or career-conditional Federal employee in the competitive service or former Federal employee who has competitive service reinstatement eligibility, you MUST submit a copy of your most recent SF-50, Notification of Personnel Action and/or a copy of the SF-50 that reflects career or career-conditional tenure in the competitive service, or you will not be considered under the Merit Promotion process. Also, you should submit your most recent Performance Appraisal.
This is a great opportunity to join a mission-driven organization with a generous benefits package; paid vacation, sick leave, holidays, health and life insurance, and excellent retirement package.
Visit our website at http://www.arts.gov/ for more information about the NEA.
This link will provide information on how to prepare a resume for Federal positions http://www.usajobs.gov/ResourceCenter/Index/Interactive/ResumeAndApplicationTips#icc.
This link will provide information on how to prepare a resume for Federal positions http://www.usajobs.gov/ResourceCenter/Index/Interactive/ResumeAndApplicationTips#icc.
As the Grants Management Specialist (Design) you will be responsible for the following tasks:
· Review and process all applications, grants, cooperative agreements and leadership initiatives from the Design field (areas such as architecture, landscape architecture, urban planning, historic preservation, industrial and graphic design) and follows all applications through the Arts Endowment's complete process from application to Final Descriptive Report.
· Counsels applicants and prospective applicants about proposed projects in context of published guidelines and with knowledge of field activities and trends as well as agency funding history of specific projects.
· In consultation with Grants and Contracts Office, monitors grantee performance through review of progress, interim and final reports, amendment requests, conversations with grantee, etc, to assure that the grantee is functioning in accordance with the terms and conditions of the grant.
· Manages items related to special design leadership initiatives that arise. Duties might include managing series of meetings and convening, webinar development and management, and other work items as they occur as well as processing cooperative agreements, interagency agreements, contracts and other government documents.
· Consults with appropriate agency staff to review and evaluate adequacy of agency policies and procedures with regard to design applications. Makes recommendations for guideline revisions and modifications of policy and procedures based on knowledge and communication with the Design Field.
Travel Required
- Occasional Travel
- Occasional travel is required to represent the NEA for local and out of town conferences and events


text:
The Routledge Critical and Cultural Theory Reader
Edited by Neil Badmington Julia Thomas
Format: Paperback
Normal Price: $68.99
Your Price: $62.09 AUD, inc. GST
Shipping: $7.95 per order
You Save: $6.90! (10% off normal price)
Plus...earn $3.10 in Boomerang Bucks
Availability: Available, ships in 7-10 days
Routledge Critical and Cultural Theory Reader by Neil Badmington
Book DescriptionEverything is open to question. Nothing is sacred. Critical and cultural theory invites a rethinking of some of our most basic assumptions about who we are, how we behave, and how we interpret the world around us. The Routledge Critical and Cultural Theory Reader brings together 29 key pieces from the last century and a half that have shaped the field. Topics include: subjectivity, language, gender, ethnicity, sexuality, the body, the human, class, culture, everyday life, literature, psychoanalysis, technology, power, and visuality. The choice of texts, together with the editors' introduction and glossary, will allow newcomers to begin from first principles, while the use of unabridged readings will also make the volume suitable for those undertaking more specialized work. Material is arranged chronologically, but the editors have suggested thematic pathways through the selections.
Buy Routledge Critical and Cultural Theory Reader book by Neil Badmington from Australia's Online Bookstore, Boomerang Books.
Book DetailsISBN: 9780415433099
(246mm x 174mm x 25mm)
Pages: 464
Imprint: Routledge
Publisher: Taylor & Francis Ltd
Publish Date: 30-Jun-2008
Country of Publication: United Kingdom
Other Editions...
Books By Author Neil Badmington
Hitchcock's Magic, Paperback (April 2011)
Why are we drawn to the work of Alfred Hitchcock so long after his final film appeared? What is the source of Hitchcock's magic? This book answers these questions by focussing upon the fabric of the films themselves, upon the way in which they enlist and sustain our desire, holding our attention by constantly withholding something from us.
Routledge Critical and Cultural Theory Reader, Hardback (June 2008)» View all books by Neil Badmington
Critical and cultural theory invites a rethinking of some of our most basic assumptions about who we are, how we behave, and how we interpret the world around us. This book contains topics including subjectivity, language, gender, ethnicity, sexuality, the body, the human, class, culture, everyday life, literature, psychoanalysis, and technology.
» Have you read this book? We'd like to know what you think about it - write a review about Routledge Critical and Cultural Theory Reader book by Neil Badmington and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a member - it's free to sign up!)
Author Biography - Neil Badmington
Neil Badmington is Senior Lecturer in Cultural Criticism and English Literature at Cardiff University. He is the author of Alien Chic: Posthumanism and the Other Within (2004) and editor of Posthumanism (2000). Julia Thomas is Senior Lecturer in English Literature at Cardiff University. She is the author of Victorian Narrative Painting (2000), Pictorial Victorians: The Inscription of Values in Word and Image (2004), and editor of Reading Images (2000).
Facebook Page | Twitter | Google+ | Bulletin e-Newsletter | Blog | RSS
Become a Member | Book Lists | Recently Released | Coming Soon | Fast Delivery Books
Bestselling Books: Our Current Bestsellers | Australia's Hottest 1000 Books | Bestselling Fiction | Bestselling Crime Mysteries and Thrillers | Bestselling Non Fiction Books | Bestselling Sport Books | Bestselling Gardening and Handicrafts Books | Bestselling Biographies | Bestselling Food and Drink | Bestselling History | Bestselling Travel Books | Bestselling School Textbooks & Study Guides | Bestselling Children's General Non-Fiction | Bestselling Young Adult Fiction | Bestselling Children's Fiction | Bestselling Picture Books | Top 100 US Bestsellers
For: Schools | Organisations | Libraries | Publishers | Authors | Book Clubs | Bloggers | Affiliates
About Us | Contact Us | Help Desk | Security | Privacy | Terms of Use | Copyright
Phone: 1300 36 33 32 (9am-5pm Mon-Fri AEST) - International: +61 2 9960 7998 - Online Form
Address: Boomerang Books, 878 Military Road, Mosman Junction, NSW, 2088
© 2003-2017. All Rights Reserved. Eclipse Commerce Pty Ltd - ACN: 122 110 687 - ABN: 49 122 110 687
For every $20 you spend on books, you will receive $1 in Boomerang Bucks loyalty dollars. You can use your Boomerang Bucks as a credit towards a future purchase from Boomerang Books. Note that you must be a Member (free to sign up) and that conditions do apply.


text:
Ahmadinejad Gets Cold Welcome from Egypt's Sunnis
Ahmadinejad Gets Cold Welcome from Egypt's Sunnis
204 results for 'the revolution'. Showing results 55 - 72
Ahmadinejad Gets Cold Welcome from Egypt's Sunnis
Iran's Christian Revolution Gains Momentum
While many are concerned about the political changes sweeping the Islamic world, some Christians are seeing another kind of...
The revolutions shaking the Middle East are having a rough impact on Christians in those nations. Jerusalem Bureau Chief...
Sexual Revolution Shaper: Brown's 'Toxic Legacy'
As seen on "The 700 Club" for July 4, top headlines from CBN News: Holiday travelers getting more bang...
'God of Liberty' Crucial to the American Revolution
American Freedom Forged in the Fire of Faith
Human Right Abuses Still Prevail after Arab Spring
Harvest of Souls: Cuba's Church Stages Comeback
For more than 50 years, being a Christian in Cuba was an invitation to persecution, but the communist nation...
1979 Islamic Revolution
Christian Worker Starts Spiritual Revolution in Iran
Stakelbeck on Terror | Inside Iran's Revolutionary Guard
Stakelbeck on Terror: Muslims Persecuting Non-Muslims
Boko Haram's 'Holy War' on Nigeria
Maspero Massacre: Egypt's Christians Cry for Justice
Calvary Chapel's Smith Says He Has Cancer


text:
|Search This Record Series:
|Record Creator:
|Methow Valley Irrigation District
These records include the minutes of the Methow Valley Irrigation District meetings from July 26, 1924 through November 2, 1939.
Minutes are the official record of the proceedings of the Irrigation District. Minutes may include date, board members present, budget approvals, and other Commission business. The records in this collection are indexed by date.
|Related Records:
|For more information or to learn about related records, contact the Washington State Archives, Central Regional Branch at (509) 963-2136 or email firstname.lastname@example.com.
|Access Restriction Notes:
|These records are open for research.
|Source of Transfer
|Central Regional Archives
|These records filmed by Washington State Archives, Imaging and Preservation Services.
|Agency History:
|Okanogan County
|Preferred Citation:
|[Identification of item], Methow Valley Irrigation District, Minutes, 1924-1939 , Washington State Archives, Digital Archives, http://digitalarchives.wa.gov, [date accessed].
|Record Count:


text:
× View Today's Deals
You missed it This great deal for Brilliant Vision is over. But don't despair, we've got more great deals every day.
Related Deals That You May Like
Brilliant Vision
Eye Exam and $200 Toward Prescription Glasses
- Save 84%
- 13 purchased
deal over
deal over!
An extensive array of designer frames from names like Fendi, Versace, and Dolce & Gabbana make finding your new look at this eye-care center a blast. Treat yourself to an updated prescription and distinctive frames to go with it:
• $40 ($250 value) for an eye exam and $200 toward prescription glasses
• Eye exam will refine your prescription and help you catch any vision issues
• Appointments or walk-ins available from 10 a.m. to 7 p.m. every day except Saturday
PAID VALUE EXPIRES ON February 28, 2022
PROMOTIONAL VALUE EXPIRES ON July 21, 2014


text:
La cama era cómoda. En coche por la zona de aparcamiento para 25 minutos buscando un lugar de estacionamiento. Tuvimos que pedir almohadas adicionales tres veces.
Todo estaba limpio, la cama era grande, y el hombre que nos atendió nos dio un par de botellas de agua cuando le preguntamos sobre cómo conseguir agua. A pesar de que era Navidad. No había nevera o microondas, y nos dieron wifi gratis porque era Navidad, pero deben ser siempre wifi gratis en un hotel, independientemente de que día es.
Most days, house keeping left no water, even though I was on the 8th floor.
The pool is big with an indoor and outdoor area. It also had a small infant pool. Fitness and locker rooms were that of a 4 diamond resort. Very friendly staff. Will stay here again.
Room and amenities. Breakfast in 0124 Restaurant was tasteless except for fruit.
The stafff exceeded expectations on many levels The gym/workout was small and the valet was often overwhelmed with events so that cabs and Uber's were backed up literally 325-30 cars behind the valet
The staff was friendly & the room was very clean The parking lots were sort of complicated.
Hotel is simply outstanding when it comes to the decor, business service amenities and location. Staff go above and beyond to help customers. Breakfast options were average- hot and cold selections
Loved the location of the hotel close to the Galleria. Even though we had a car, we were a le to walk to stores and restaurants. Enjoyed the suite and cleanliness of the hotel. Staff was great and we enjoyed the breakfast and happy hour. Will come back again.
Rooms are beautiful--tastefully decorated, bright, comfortable, well laid-out. Complimentary breakfast is comprehensive. Manager's receptions during the week have good appetizers and wine and beer. Really comfortable here.
I had a change of plans that required I drive into Houston earlier than the 3PM check in time. The staff gave me a temporary room to make a clothing change and stored my luggage until I was able to check in after my function. Everyone was so courteous and made my stay that much better. I will book there again without hesitation. The area was close to everything.
There is only one thing I don't like is why I have to pay extra for parking when I stay at their hotel.
Although the hotel was showing its' age, the hotel staff and everyone taking care of our room and the breakfast was superb! Can't say enough about the service we got! Would definately recommend, especially since this was a suite hotel and had lots of moving room in our room!
I was very impressed. The room was extremely functional.
The price was good. The staff was friendly. However, I could not help but to feel cheated. These 'suites' are not what you get some where like the Homewood suites where there are two separate rooms (TV room and bed room) these suites were one big room with bookshelves in between. Not good when you want to put two kids to sleep and enjoy some time. The pool was great during the day. At night forget it, its pitch dark I relayed my concerns to the front t desk who adviced me the lights were not working apparently due to some glitch in the remodeling process (they are in middle of extensive renovation). One more thing, the parking garage has a card reader which allows you to access the premises, it?s in the back of the property through a narrow alley, when my wife made the turn into the card reader, she took the turn INTO the card reader. My wife?s fault totally but just something to watch out for, she claims that card reader came out of nowhere and hit her.
Wonderful location and on site parking. The staff was very welcoming and accommodating. Breakfast and coffee were good and I would definately stay here again.
Overall this was a great hotel. In our room we especially appreciated the shower, bed, pillows and revolving tv. The shower was amazing with great pressure. The bed and pillows were extremely comfortable. We almost did not want to get out of bed in the morning. The room was spacious and laid out very well allowing plenty of room for furniture not often seen a hotel room. The mirror in the closet with a plug next to it made it so efficient to put makeup on and do hair while others used the bathroom. The price was even better. Out of all the hotel chains we have stayed at this was far one of the better rooms. We will definitely stay here next time we are in Houston.
Good customer service. None
Everything perfect, thank you so much No
The hotel was nice and clean and location was fine The TV did not work, we could not watch the World Series, the phone did not work, called the front desk on my cell phone and they could care less that the TV didn't work, many pictures of sausage & egg biscuit sandwiches but they had no biscuits.
Staff Yes maid service and the air conditioner didn't cool in room 208
The room was clean Nop
Full breakfast Telephone did not work, discovered someone had cut the line in the bedroom and had to wait for a new one. Same day, the TV service went out. Turns out they were switching providers and never communicated that to me. Front desk lady was not helpful.
This hotel is not 3 star at all Bed are cheap and very uncomfortable
I enjoyed that the hotel was affordable and seemed nice for the price. The hotel had a peculiar odor in my room and there was hair in my toilet.
The day staff The room smell .the sheet had spots on them the water didn't Get hot I reported I was there 7 days
This guest did not leave comments about this hotel.
The staff was VERY friendly and fulfilled every need. Breakfast was GREAT. The lobby area was immaculate and smelled wonderfully of fresh cookies. The rooms were a bit damp and musty. Probably flooded in the past. There is NO elevator in the building. Not such a bad thing once established in the room but I would have very much disliked carrying two loads of heavy luggage upstairs.
Excellent value, roomy (suite), clean. Not crowded. Easy parking. Close to many restaurants. The soap was not very good quality (it was drying).
The room was comfortable and the location is great for family. Cable and wi-fi was excellent. The room air-conditioner didn't get cold, just cool enough to be comfortable. Breakfast time was way too loud. I suggest a sign be placed up to be noticed. People were over talking each other.Very rude. The hash browns weren't cooked. Yes, I mean just raw potatoes dumped in a crock-pot. The coffee should be changed as it was tasteless. Other items were tasty.
This is very convenient location for me, I will stay here when I have a business trip in Houston
Clean rroms, friendly helpful staff. great breakfast
spotless room - entire hotel was immaculate! Everything seemed brand new? no ice in the ice machine and only one ice machine on first floor only - book in room said otherwise. Otherwise I would have given them a perfect score!
Nice staff
The pool,the service the room
The cleanliness and the size of the room and bathroom and the friendliness of the staff members. None.
Room with 1 King was great and the pillows are Wonderful. Very friendly and personable staff. Good breakfast, many selections, pleasing dining room dC)cor.
Front desk staff was welcoming Unfriendly rude server at the breakfast bar. Coffee served room temperature. Maid did a half-ass job making the beds. Worst hotel stay I have had in 15 years.
We were in Houston for my sons 25 Birthday and reserved a room at the hotel for the convience (my son lived about 6 blocks from there). I know that Marriotts are always nice hotels but the Fairfield was wonderful. The staff was very polite and courteous and always helpful. They worked hard to keep things clean and neat. I usually hate the pillows and beds at hotels but these were wonderful, like sleeping on a cloud. We will certainly use them again when we are in town.
This was exceptionally great hotel, Everything is great. Great Staff members , Great Breakfast and specially omelet making. Nice Laundry and Computer desk for Kids in breakfast room.
Morning omelet station for cooked to order omelets was a very nice touch. The hotel is clean and well maintained with security patrol on site. Nothing
Almost everything I needed was there. I didn't really use the well-equipped kitchen, but I certainly could have! All items were sparkling clean. The courteous and accommodating staff were exceptional. Good breakfast too! The laundry facilities were nearby, but in another building.
I stay here often I really like everything. I couldnt get the bed type I wanted.
Everything Nothing
This guest did not leave comments about this hotel.
This guest did not leave comments about this hotel.
This guest did not leave comments about this hotel.
This guest did not leave comments about this hotel.
Everything No
The Hyatt House is my new favorite! Breakfast is off the charts!
Great room with a great bed. Felt like a suite with a large sectional couch and decent sized flat screen TV that could be swung 360 degrees. Nice kitchenette with full-sized fridge. Cool tiled-in walk-in shower (I hate bathtubs)! Not complaining, because it was free, but the complimentary breakfast was pretty bad. If you're an egg eater, you might feel differently, because they have a dual omelette cooking station, but the remainder of the hot breakfast foods were horrible.
This place was super clean and smelled great. The beds were super comfortable. Loved the Kureig coffee pot in the room but the complimentary coffee in the lobby was even better. The staff was verry professional and nice. Only heard someone in the hallway once which was early Saturday morning other than that never heard a sole in or three night stay. The saltwater pool was nice and never crowded and I loved the waterfall. Overall this was the best hotel I've stayed at other than a really high end Sofitel I stayed at in London. Pool was a little cloudy and small and there were birds that loved to take a bath in the waterfall feature. This was not a huge deal but made me a little uneasy about the safety of the pool. Additionally the complimentary coffee was not sat out until 7ish I would have liked if it was sat out earlier for the early risers.


text:
Bob's Auto Repair and Collision Center is a true full service automotive repair facility, they can handle your mechanical service and repairs as well as your collision repair needs. This location has been family owned and operated for over 30 years. Our evaluation revealed that this RepairPal Certified shop has been voted "#1 Auto Repair Facility" for the past 14 years in a row. This was backed in our unbiased survey of their recent customers who describe this team as efficient, friendly, convenient, and fair. This location features a team of every experienced professionals who take the time to attend the ongoing training that is necessary to make professional repairs to your modern vehicle. This training, coupled with an investment in the necessary automotive tools and computer diagnostic equipment make this a great place for dealership level repairs. The mechanical work done here is backed by a 24-month / 24,000-mile warranty for your peace of mind. Local shuttle service, early bird drop off, and a waiting area with wireless Internet are available for your convenience.
Bob's Auto Repair & Collision Center
Tallahassee, FL 32304 USA
- 09:00
- 18:00
- http://purl.org/goodrelations/v1#Monday
- 09:00
- 18:00
- http://purl.org/goodrelations/v1#Tuesday
- 09:00
- 18:00
- http://purl.org/goodrelations/v1#Wednesday
- 09:00
- 18:00
- http://purl.org/goodrelations/v1#Thursday
- 09:00
- 18:00
- http://purl.org/goodrelations/v1#Friday
Auto Repair Experience
- Misty Sullivan, Service Manager
- Established 1982
- 3 Auto Repair Mechanics on Staff
- 95 Years of Car Repair Experience
- AC/Heating
- Check Engine Light
- Classic Car Repair/Restoration
- Collision Repair & Paint
- Diagnosis
- Hybrid/Electric
- Muffler & Exhaust
- Oil Change & Lube
- Scheduled Maintenance
- Service & Repair
- Timing Belts
- Tire Sales/Repair
- Transmission Repair
- Windshield/Glass
- AAA Member Discount
- Extended/Evening Hours
- Financing
- Free Estimates
- Free Multi-Point Safety Inspection
- Military Discount
- Rental Car
- Senior Discount
- Service Guarantee
- Towing
- Warranty Accepted
- Wireless Internet
Makes We Serve
- Acura
- Audi
- Buick
- Cadillac
- Chevrolet
- Chrysler
- Dodge
- Ford
- Geo
- Honda
- Hummer
- Hyundai
- Infiniti
- Isuzu
- Jaguar
- Jeep
- Kia
- Land Rover
- Lexus
- Lincoln
- Mazda
- Mercedes-Benz
- Mercury
- Mini
- Mitsubishi
- Nissan
- Oldsmobile
- Plymouth
- Pontiac
- Porsche
- Ram
- Saab
- Saturn
- Scion
- Smart
- Subaru
- Suzuki
- Toyota
- Volkswagen
- Volvo
Overall Rating
They're fast and close to my home.
Free diagnostic test when you go in. They're speedy and they're quick.
That is my daughter's business, and they do good work.
Quick & affordable. They're nice, and they're good.
I have been happy with the service. It was quick, they only did the work that needed to be done and in a timely manner, and at a fair price.
They have been rated well on community based recommendations. They have excellent customer service, and the best prices.
I go there when I need their help, they are pretty good people. They are knowledgeable and very helpful, if they don't know something they will take the time to learn whatever they need to.
They didn't have my car ready when they said they would, and after I left I found that my estimate was 500 dollars more than it should have been.
It was quick, and they got the job done.
I have always had good service.
Fair and honest. Convenient and get you in when its an emergency.
They're helpful, friendly, fast, and work quickly. Having a car is important and they take good care of me. Conveniently located. I have had no problems.
Great service and discounts for University students. They're honest in what they do.
They have the lowest prices around, they did the work fast and were honest about what needed to be done and that is why I trust them as a merchant.
Quick service and great customer service, since I only went in for a 20 minute diagnostic.
Nice and friendly, and not too expensive.
He got the job done correctly and quickly.
They are the cheapest and most efficient to help us out. They're always pretty quick and done in the day. I went to one other place and they charge way too much.
I was really satisfied with the work done, it looked like a brand new vehicle when they were through and at 400 dollars cheaper than the other shops.
I brought my truck in for a new transmission, they had my truck there for almost a month. The first two transmissions didn't work.
They are good people and have fair prices, and they do a good job.
I have been going there off and on for the past 5 years and they do a good job. Whenever I have a problem with my car I never have the same issue afterwards.
They kept me informed throughout the repairs, did a good job and at a quick pace.
I have been going there for over 4 years with great results. They have good professionalism, do the job right the first time and great prices.
- High quality repair
- Guaranteed fair prices
- Real, verified reviews
- Current expert training
- Warranty on repairs
- Great customer service


text:
Kesa Electricals has sold Comet to the private investment firm OpCapita for a nominal fee of just £2. But the parent company was forced to pump £50m into the loss-making UK electricals chain and retain its pension liabilities to get rid of Comet.
To safeguard the 248-store chain's future, Comet will receive a total of £120m, with OpCapita putting in £30m of equity and Burdale, a subsidiary of Bank of Ireland, providing an asset-backed loan of £40m.
The sale of Comet caps a tumultuous week for the UK electricals sector and comes just two days after Best Buy UK said it will close its 11 stores before Christmas. The market is suffering from a slump in consumer spending on big-ticket items and the structural shift to online. OpCapita intends to run Comet as a going concern for at least 18 months from the expected completion of the deal in February. The investment group denied speculation that it plans to close waves of Comet's shops.
An OpCapita spokesman said: "At this stage, we don't intend for there to be a significant store closure programme or significant redundancies."
OpCapita believes it can improve Comet's performance in areas such as selling higher-margin products, growing online and trimming costs. Market sources believe it plans to cut costs at Comet's head office, for instance.
But Matt Piner, the lead consultant at Conlumino, said: "Comet's new owner faces a gargantuan challenge to return the brand to success."
Kesa put Comet up for sale in June following pressure from shareholder Knight Vinke, which wants it to focus on its Darty chain on the Continent.
While Kesa will get a return if Comet is sold for more than £70m, David Newlands, the group's chairman, said: "We had to pay them [OpCapita] to sell the business... But we are writing that £50m off."
- More about:
- Bank Of Ireland Group
- Europe
- Investment
- Loans And Lending Market


text:
Hesitation when starting off in first gear.
While driving my Jeep today I noticed my 2012 hesitates when I start from a stop. I know how to drive manual so I don't think its my doing. Soon as I touch the gas and start letting off the clutch the rpms dip for a second then I gotta mash the gas to get it going before it dies. Its as if there is a dead space for about a half an inch or so in my gas pedal. I've killed this Jeep more than any manual I have ever owned. The problem with mashing the gas is its starting to get winter time here and the last thing I need is my tires spinning out of control because I have this dead space. Is there any way to fix this? Does anyone else have this issue? Do I just suck at the JK clutch?:hide:
It's cold in Illinois isn't it? Did you let the car warm up?
Get a sprint booster, or remove one spring from the pedal, I did the former and it helped a lot (night and day), Wrangler's gas pedal (at least mine) is the worst I have used, it's heavy and laggy and not very communicative.
Were you on a hill? The JK's with manual tranny's have hill assist, which keeps the brake engaged when you release the brake pedal, giving you time to transition to the gas pedal without the Jeep rolling. I can't remember at what angle it kicks in. I have played with mine, and it doesn't matter how hard I press the brake pedal in. Some on here have stated that it is proportional to how hard you are depressing the brake pedal, but in my experimentation that hasn't been the case. Drive to where you have the Jeep pointing uphill and come to a stop. Then just release the brake pedal and you will see there is a pause of a second or two before it will start to roll backwards. Play with it a little bit, and get a feel for how ling it takes to disengage the brake.
I'm going to take mine off when I get it back from the shop. After a week of driving I hated it. Feel like I'm wearing my brakes faster.
If you play with it you can get a feel for the timing of when it will disengage the brake. Is there an easy way to shut-off the hill assist?
If you wish to turn off the HSA system, follow this procedure:
1. Start with the engine off and vehicle in PARK (auto- matic transmission) or NEUTRAL with clutch out (manual transmission) with wheels straight. Apply park- ing brake on manual transmission vehicle.
2. Start the engine.
3. With the engine running, the brake applied, and the clutch out, rotate the steering wheel 180° counterclock- wise from center.
4. Press the ESC OFF switch four times within twenty seconds.
5. Rotate the steering wheel 360° clockwise (180° clock- wise from center).
6. Cycle ignition switch OFF then ON.
7. If the sequence was completed properly, the ESC Activation/Malfunction Indicator Light will blink sev- eral times to confirm HSA is off.
Steps 1-7 must be completed within 90 seconds to turn off HSA. Repeat steps 1-7 to re-enable HSA functionality.
Thanks for the info.
My HSA is off and my Jeep does the same thing.
while operating; release break pedal before engaging the clutch pedal.. proceed
Its not just you. Ive driven standard for 30 years. Started off in a land rover at all of 10 years old. This is the only vehicle ive had that frequently stalls. Hill start is disabled. Its left me hung out to dry a few times in a busy intersection. Quite a scary experience. Find it worse backing up. Especially on any incline. Oddly in reverse, if i dont touch the gas its no problem. Give it slight gas and it will stall easily. Its very weird. You can feel the engine start to struggle, put the clutch in immediately and it will still judder and die. Some fueling issue i guess. Or Hopefully an ignition timing upgrade will fix it at some point. Seems a bit useless that a jeep stalls easily at low speed. First time i wished id went auto.
I find my self hugging the clutch to keep it from dying. I'm sure it will burn out eventually and I can go rage at the dealer.
Take you foot completely off the gas until the clutch is fully engaged. Then give it a little gas.
The JK electronic throttle will attempt to keep the engine running at idle speed at whatever torque requirement as long as your foot is completely off the gas.
Then, when you step on the gas, the "drive by wire" feature takes over.
At that time, if you are in the "transition", your engine will hesitate.
I have killed mine I don't know how many times while wheeling when I am just letting the electronics do their thing, and then try to just "feather" the gas pedal to get a little more wheel speed while negotiating a steep climb.
Hope all this helps you guys and gals out.
Maybe someone better at typing and all can give a better description of what is going on with the JK "drive by wire" throttle.:thumb:
I don't get what your saying?
Push clutch to floor
let it all the way out? (this would kill it)
then press gas?
I'm lost
Exact same thing here. Best I can figure is that the rpm dips to less than 1,000 where the torque and hp are low. If I cared enough, I'd do the math to figure out that torque applied at that time to the rear wheels was insufficient to overcome initial friction. I've learned that keeping the rpm up around 1200 works.
I'm hoping new rear gears keeps this from happening but we shall see.
i noticed recently, i have a tendency to release the clutch ..fully, and then apply the gas; after initial acceleration. am i still getting accustom to the high release/engagement point on the pedal? i don't know.. but i caught myself doing it with a conscious mind lol
4351 Attachment(s)
With my superchips tune my 07 doesn't lug under under 2K even with 35's.
I can cruise at 1700 easily without lugging.
The sprintbooster/SC combo make drivability 10x better.
Driving a Tj for 10 years, the step up to a JK was a smack in the face.
First mod was the sprintbooster. The tune was more noticeable when I moved up to 35's.
I know the OP posted about his 12 but both the 3.8/3.6 suffer at lower rpms.
I thought it was me. I've been driving stick for 40yrs, yeah I'm an old fart, and never had a problem. The clutch engages early enough, but it doesn't do it gradually. It goes from light engagement to full engagement very quickly. I stalled out more in the 1st 2 weeks than I have in 40 yrs. takes some getting used to, but I finally have it down. Still wouldn't want an auto.
Welcome to the forum. :thumb:
I agree with the suggestions that staying off the throttle seems to be the solution.
Im hoping that some kind of power control module will come out soon and that may help things.
|All times are GMT -5. The time now is 10:07 AM.
User Alert System provided by Advanced User Tagging v3.1.0 (Pro) - vBulletin Mods & Addons Copyright © 2017 DragonByte Technologies Ltd.
vBulletin Security provided by vBSecurity v2.2.2 (Pro) - vBulletin Mods & Addons Copyright © 2017 DragonByte Technologies Ltd.


text:
How We Test Security SoftwareBy Neil J. Rubenking 02.21.2017Read More >
The Best Antivirus Protection of 2017By Neil J. Rubenking 02.21.2017Read More >
The Best Free Antivirus Protection of 2017By Neil J. Rubenking 02.16.2017Read More >
The Best Password Managers of 2017By Neil J. Rubenking 02.15.2017Read More >
F-Secure Sense IoT Security Device Coming SoonBy Neil J. Rubenking, Max Eddy 02.15.2017Read More >
Panda Free Antivirus (2017)
Bottom Line: Panda Free Antivirus boasts an attractive user interface and an unusual USB vaccination feature, but its scores have slipped in both our tests and independent lab tests.
Avast Free Antivirus 2017
Bottom Line: Avast Free Antivirus 2017 combines a great free antivirus with a surprisingly extensive collection of bonus features.
The Best Security Suites of 2017By Neil J. Rubenking 02.07.2017Read More >
Comodo Internet Security Complete 10
Bottom Line: Comodo Internet Security Complete 10 offers online backup, automatic VPN, and instant access to GeekBuddy remote tech support. However, we ran into problems with all three features, and the antivirus had issues in testing.
TrustPort Total Protection Sphere (2017)
Bottom Line: TrustPort Total Protection Sphere takes TrustPort's lackluster entry-level suite and adds a collection of bonus features, many of which won't benefit the average user.
G Data Total Security 2017
Bottom Line: G Data Total Security 2017 adds significant bonus features that are well worth the price bump from the company's entry-level suite.
AVG Internet Security - Unlimited (2017)
Bottom Line: As the name implies, AVG Internet Security - Unlimited lets you install protection on an unlimited number of Windows, macOS, and Android devices. However, other cross-platform multi-device suites do the job better.
Comodo Internet Security Premium 10
Bottom Line: Comodo Internet Security Premium 10 merges Comodo's standalone antivirus and firewall programs and adds a new secure shopping environment. That's a lot of features for a free product, but some aren't very effective.
TrustPort Internet Security Sphere (2017)
Bottom Line: TrustPort Internet Security Sphere has a new name and a new look, but under the hood it shows little improvement. Look elsewhere for your security suite needs.
G Data Internet Security 2017
Bottom Line: G Data Internet Security has all the components you expect in a suite, and even adds backup. However, component quality varies from very good to very poor.
McAfee Total Protection (2017)
Bottom Line: To the feature set of McAfee's entry-level suite, Total Protection adds file encryption and four additional licenses for the True Key password manager. Best of all, you can install it on every device in your household.